Artelo Biosciences (NASDAQ:ARTL) Announces Quarterly Earnings Results

Artelo Biosciences (NASDAQ:ARTL) released its earnings results on Wednesday. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.04), MarketWatch Earnings reports.

Shares of Artelo Biosciences stock traded down $0.04 on Friday, reaching $0.97. 36,818 shares of the company were exchanged, compared to its average volume of 5,222,977. Artelo Biosciences has a one year low of $0.45 and a one year high of $4.42. The company has a market capitalization of $14.64 million, a price-to-earnings ratio of -0.79 and a beta of 2.52. The company has a 50-day moving average of $0.71 and a 200 day moving average of $0.85.

Separately, Maxim Group upgraded Artelo Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, January 7th.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD.

Further Reading: Trading Strategy Examples and Plans

Earnings History for Artelo Biosciences (NASDAQ:ARTL)

Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit